Docetaxel Skin Exposure and Micronucleation Contributes to Skin Toxicity Caused by CPC634.

chemotherapy docetaxel nanoparticles pharmacodynamics pharmacokinetics skin toxicity

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
26 Jul 2021
Historique:
received: 01 06 2021
revised: 21 07 2021
accepted: 21 07 2021
entrez: 7 8 2021
pubmed: 8 8 2021
medline: 8 8 2021
Statut: epublish

Résumé

Docetaxel entrapped nanoparticle CPC634 is associated with dose-related skin toxicity that resembles conventional docetaxel (Cd)-related skin toxicity. This study compared the cutaneous pharmacokinetics and pharmacodynamics of docetaxel and CPC634. In this randomised cross-over study, patients with solid tumours received one cycle of CPC634 and Cd (both at 75 mg/m

Identifiants

pubmed: 34359641
pii: cancers13153741
doi: 10.3390/cancers13153741
pmc: PMC8345028
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Cristal Therapeutics
ID : NA

Références

Support Care Cancer. 2015 Jul;23(7):1917-23
pubmed: 25487841
Eur J Dermatol. 2016 Oct 1;26(5):427-443
pubmed: 27550571
Support Care Cancer. 2015 Nov;23(11):3269-75
pubmed: 25933700
J Clin Oncol. 1995 Oct;13(10):2643-55
pubmed: 7595719
J Control Release. 2020 Sep 10;325:191-197
pubmed: 32590047
Open Biol. 2017 Nov;7(11):
pubmed: 29142107
Nat Rev Clin Oncol. 2010 Nov;7(11):653-64
pubmed: 20838415
J Pharm Biomed Anal. 2018 Nov 30;161:168-174
pubmed: 30165333
Postgrad Med J. 1976 Oct;52(612):631-3
pubmed: 995788
Eur J Cancer. 2005 May;41(8):1117-26
pubmed: 15911234
Nano Today. 2015 Feb 1;10(1):93-117
pubmed: 25893004
Biomaterials. 2015;53:370-8
pubmed: 25890735
Support Care Cancer. 2013 Oct;21(10):2679-86
pubmed: 23686402
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
Arch Dermatol. 1995 Feb;131(2):202-6
pubmed: 7857119
Clin Cancer Res. 2020 Jul 15;26(14):3537-3545
pubmed: 32321718
Cancer Manag Res. 2014 May 27;6:253-9
pubmed: 24904223
Int J Nanomedicine. 2020 Oct 22;15:8151-8166
pubmed: 33132699
Cancer Treat Rev. 2003 Oct;29(5):407-15
pubmed: 12972359

Auteurs

Florence Atrafi (F)

Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.

Ruben A G van Eerden (RAG)

Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.

Stijn L W Koolen (SLW)

Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.
Department of Hospital Pharmacy, Erasmus MC, 3015 GD Rotterdam, The Netherlands.

Peter de Bruijn (P)

Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.

Cristianne J F Rijcken (CJF)

Cristal Therapeutics, 6229 EV Maastricht, The Netherlands.

Rob Hanssen (R)

Cristal Therapeutics, 6229 EV Maastricht, The Netherlands.

Ferry A L M Eskens (FALM)

Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.

Martijn P Lolkema (MP)

Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.

Esther Oomen-de Hoop (E)

Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.

Jeffrey Damman (J)

Department of Pathology, Erasmus MC, 3015 GD Rotterdam, The Netherlands.

Ron H J Mathijssen (RHJ)

Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands.

Classifications MeSH